ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT06464692
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University /ID# 263193, Nanchang, Jiangxi, China
🇨🇳Beijing Cancer Hospital /ID# 263297, Beijing, Beijing, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 263309, Guangzhou, Guangdong, China
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 675
- Registration Number
- NCT06461897
- Locations
- 🇵🇹
Unidade Local de Saude de Sao Joao, EPE /ID# 266111, Porto, Portugal
🇺🇸Applied Research Center Of Arkansas /ID# 268547, Little Rock, Arkansas, United States
🇺🇸Integrative Skin Science and Research /ID# 265108, Sacramento, California, United States
Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease
- Conditions
- Ulcerative ColitisCrohn's Disease
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 600
- Registration Number
- NCT06459297
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 270014, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷SoonChunHyang University Hospital Cheonan /ID# 270015, Cheonan-si, Chungcheongnamdo, Korea, Republic of
🇰🇷The Catholic University of Korea, Daejeon St. Mary's Hospital /ID# 267843, Daejeon, Daejeon Gwang Yeogsi, Korea, Republic of
An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- Conditions
- Dry Eye
- Interventions
- Drug: Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 47
- Registration Number
- NCT06443775
- Locations
- 🇺🇸
Saint Louis Eye Institute /ID# 263275, Town And Country, Missouri, United States
An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- Conditions
- Dry Eye
- Interventions
- Drug: Optive MEGA-3 (OM3)
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 52
- Registration Number
- NCT06439394
- Locations
- 🇺🇸
Southern College of Optometry /ID# 262668, Memphis, Tennessee, United States
Expanded Access to ABBV-787
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06439966
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT06428019
- Locations
- 🇺🇸
West Virginia University School of Medicine /ID# 267645, Morgantown, West Virginia, United States
🇺🇸Arizona Oncology - Tucson - Rudasill /ID# 267552, Tucson, Arizona, United States
🇺🇸UCSF FRESNO/Community Cancer Institute /ID# 270874, Clovis, California, United States
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1000
- Registration Number
- NCT06421740
- Locations
- 🇨🇳
Beijing Anzhen Hospital /ID# 273443, Beijing, Beijing, China
🇨🇳China-Japan Friendship Hospital /ID# 274778, Beijing, Beijing, China
🇨🇳Peking University First Hospital /ID# 274865, Beijing, Beijing, China
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.
- Conditions
- Healthy Volunteers
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06414798
- Locations
- 🇺🇸
Acpru /Id# 264249, Grayslake, Illinois, United States
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 450
- Registration Number
- NCT06417775
- Locations
- 🇺🇸
Central Research Associates /ID# 260161, Birmingham, Alabama, United States
🇺🇸MD First Research - Chandler /ID# 262564, Chandler, Arizona, United States
🇺🇸Gilbert Neurology Partners, PLLC/CCT Research /ID# 260179, Gilbert, Arizona, United States